Jiawei Xiaoyao capsule treatment for mild to moderate major depression with anxiety symptoms: a randomized, double-blind, double-dummy, controlled, multicenter, parallel-treatment trial.

Objective: To assess the efficacy and safety of Jiawei Xiaoyao (JWXY) capsules on mild to moderate depression with anxiety symptoms, a randomized, double-blind, double-dummy controlled, multicenter, parallel-treatment trial was carried out among 210 outpatients with mild to moderate depression and anxiety symptoms from three hospitals in Beijing China.

Methods: Participants were randomized into the JWXY group or the sertraline group. Each group received JWXY treatment and sertraline placebo, or sertraline and JWXY placebo for 8 weeks.